A UAE real-world case series reported clinically meaningful improvements associated with ravulizumab in patients with generalized myasthenia gravis. The report highlights benefit at the individual level and provides practical observational context beyond clinical trial endpoints. For clinicians and payors, the signal points to how complement inhibition may translate into everyday outcomes, though the study design limits generalizability. Still, case series can help frame endpoints for future prospective evidence and guide expectations for response monitoring.